The Rise of Herpes Simplex Virus Treatment Market
The global herpes simplex virus (HSV) treatment market is witnessing steady growth as healthcare providers, pharmaceutical companies, and governments intensify their focus on managing the high global burden of HSV infections. Valued at USD 2.8 billion in 2024 , the market is forecasted to grow at a CAGR of 5.5% between 2025 and 2034 , reaching USD 4.3 billion by 2034 . HSV is a highly prevalent viral infection caused by HSV-1 and HSV-2 , responsible for oral and genital herpes respectively. According to the World Health Organization (WHO), around 3.7 billion people under the age of 50 have HSV-1 infection , while 491 million aged 15–49 live with HSV-2 , highlighting the vast unmet need for effective treatments. The treatment landscape currently relies on antiviral drugs such as acyclovir, valacyclovir, and famciclovir , which help reduce symptoms, frequency of outbreaks, and transmission risk but do not cure the infection....